Skip to contentB
Bio-Rad Laboratories, Inc.
B
BIOBio-Rad Laboratories, Inc. Q1 2023 · 10-Q
Revenue$676.84M$676.84M−3.3% vs Q1 2022 Net Income$69.00M$69.00MN/M vs Q1 2022 EPS Diluted$2.32$2.32N/M vs Q1 2022 Gross Profit$362,400,000−10.0% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Bio-Rad Laboratories, Inc. · CIK 12208 · Engraved from SEC EDGAR
Operating Cash Flow$98,119,000+94.3% Free Cash Flowderived$62,394,000+258.3% Margins · derivedGross margin53.5%−4.0 pt vs Q1 2022
Operating margin9.1%−11.8 pt vs Q1 2022
Net margin10.2%+491.2 pt vs Q1 2022
ended Mar 31, 2023 · filed May 5, 2023 · 35 d after period end